Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 19.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
100.0%-83.0 pp YoY
LTMMar 2026
-17996.6%-16820.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-83.0 pp——
3 years+19.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
-83.0pp

Gross Margin vs competitors

How AVTX compares with its peers on the latest reported figures

  • AVTX's LTM Mar 2026 gross margin of -17996.6% is the 6th highest of the 7 companies compared; the peer median is 63.2%.
  • Its year-over-year change of -16820.4 pp is the 4th highest of 5, against a peer median of +18.9 pp.
  • Over three fiscal years its change of +19.0 pp compares with a peer median of +63.2 pp.
AVTX Competitors Peer median
Gross Margin for AVTX and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 2026116.4% +166.6 pp+862.2 pp
QTTBQ32 Bio Inc.LTM Mar 202699.3% —-0.7 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
SYRESpyre Therapeutics, Inc.LTM Sep 202650.0% ——
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-17996.6% -16820.4 pp+19.0 pp
IFRXInflaRx N.V.LTM Mar 2026-24646.3% -22352.6 pp—
ODTXOdyssey Therapeutics, Inc.—— ——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024— ——
ELDNEledon Pharmaceuticals, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
Peer median (excluding AVTX) 63.2%+18.9 pp+63.2 pp

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.